Australia - English - Department of Health (Therapeutic Goods Administration)

ix biopharma pty ltd - cannabidiol, quantity: 50 mg - wafer - excipient ingredients: carmellose sodium; mannitol; lactose monohydrate; potato starch; glycine; macrogol 1500; microcrystalline cellulose; sucralose; polysorbate 80; brilliant blue fcf; quinoline yellow; purified water; flavour

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - clobazam - oral tablet - 10mg

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - clobazam - tablet - 10 milligram(s) - benzodiazepine derivatives; clobazam

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - sirolimus -

United States - English - NLM (National Library of Medicine)

md natural health llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987), histamine dihydrochloride (unii: 3poa0q644u) (histamine - unii:820484n8i3) - helps in temporary pain relief

United States - English - NLM (National Library of Medicine)

md natural health llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987), histamine dihydrochloride (unii: 3poa0q644u) (histamine - unii:820484n8i3) - helps in temporary pain relief

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - temsirolimus, quantity: 30 mg - injection, solution - excipient ingredients: polysorbate 80; macrogol 400; ethanol absolute - temsirolimus is indicated for the treatment of advanced renal cell carcinoma.,torisel is indicated for the treatment of advanced renal cell carcinoma. torisel is indicated for treatment of patients with relapsed and/or refractory mantle cell lymphoma.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - sirolimus - graft rejection; kidney transplantation - immunosuppressants - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued. rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.,

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastic agents - renal-cell carcinomatorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (rcc) who have at least three of six prognostic risk factors.mantle-cell lymphomatorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (mcl).

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - everolimus 10mg;  ;   - tablet - 10 mg - active: everolimus 10mg     excipient: butylated hydroxytoluene crospovidone hypromellose lactose lactose monohydrate magnesium stearate - the treatment of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not amenable to surgery. the evidence is based on change in sega volume. further clinical benefit, such as improvement of disease-related symptoms, has not been demonstrated.